IL32 and neoplasm: Clinical evidence, supported by single‐cell RNA sequencing and multiplex immunostaining of tumor tissues, confirms the presence of IL32‐expressing pericytes closely interacting with β5‐integrin‐expressing cancer cells in EGFR‐mutated patients, impacting therapeutic response and prognosis.